ICER glosses over significant progress in MS treatment

Multiple sclerosis (MS) is a devastating chronic autoimmune disease that can affect a person’s brain, spinal cord and optic nerves, causing problems with vision, balance, muscle control and other...
Read More
Panel releases best practices in cost-effectiveness analysis

Recently, the Journal of the American Medical Association (JAMA) published findings and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine, detailing what the authors...
Read More
ICYMI: More than 60 PhRMA company scientists visit Capitol Hill

Last week, PhRMA brought more than 60 member company researchers and scientists to Capitol Hill for a biopharmaceutical researcher fly-in. The fly-in highlighted the important science that’s...
Read More
ICYMI: Multi-stakeholder group recommended changes to support value-driven health care

As part of PhRMA’s efforts to explore policy solutions to promote value-driven health care, we recently participated in a forum convened by Deloitte and the Network for Excellence in Health...
Read More
Making drug formulary search tools better for patients

There is a real need for patients to have information about out-of-pocket costs and clinical tools being used when it comes to their coverage. A new prescription drug search tool that includes...
Read More
ICER puts hard-fought progress in non-small cell lung cancer treatment at risk

Lung cancer is the leading cause of cancer death among men and women in the United States, and each year, tens of thousands of Americans are diagnosed with the most common form, non-small cell lung...
Read More
Improving FDA’s combination product review process could increase epinephrine auto-injector competition

Combination products that consist of a medicine and delivery device are important treatment options for patients and have the potential to improve public health. Innovator companies invest in...
Read More
Empowering consumers and improving access to important clinical information

Even though more Americans are insured than ever before, many are facing insurance barriers that may interfere with a doctor’s prescribed course of treatment and impact their care. We recently...
Read More
340B Spotlight: Retail pharmacies continue to expand the 340B program

One area of needed reform in the 340B program is the use of contract pharmacy arrangements. A new analysis by Drug Channels found more than one-in-four retail, mail and specialty pharmacies in the...
Read More
340B Spotlight: New report raises questions about eligibility metric for 340B hospitals

A new report from the Government Accountability Office (GAO) on how hospitals qualify for certain uncompensated care payments raises questions about how a similar eligibility metric is used to...
Read More